Dexcom (NasdaqGS:DXCM) Q4 2025 Earnings call February 12, 2026 04:30 PM ET Company ParticipantsDavid Roman - Managing DirectorJake Leach - President and CEOJereme Sylvain - CFOJoanne Wuensch - Managing DirectorJosh Jennings - Managing DirectorMarie Thibault - Managing DirectorMatt Taylor - Managing DirectorRichard Newitter - Managing DirectorSean Christensen - VP of Finance and Investor RelationsTravis Steed - Managing DirectorZachary Day - Equity Research AssociateConference Call ParticipantsBrandon Vazque ...

Expedia Group (NasdaqGS:EXPE) Q4 2025 Earnings call February 12, 2026 04:30 PM ET Company ParticipantsAriane Gorin - CEOEric Sheridan - Managing DirectorLee Horowitz - Co-Head of Internet Equity ResearchMark Mahaney - Senior Managing DirectorNaved Khan - Managing DirectorRob Bevegni - VP of Investor RelationsScott Schenkel - CFOConference Call ParticipantsConor Cunningham - Director and Travel and Transports AnalystDeepak Mathivanan - Senior Equity Research AnalystJed Kelly - Managing Director and Equity Re ...

AVITA Medical (NasdaqCM:RCEL) Q4 2025 Earnings call February 12, 2026 04:30 PM ET Company ParticipantsBen Atkins - VP of Investor RelationsCary Vance - Interim CEODavid O'Toole - CFOConference Call ParticipantsIan Arndt - Equity Research AnalystJosh Jennings - Equity Research AnalystRyan Zimmerman - Equity Research AnalystOperatorday, and thank you for standing by. Welcome to the AVITA Medical, Inc. fourth quarter and full year 2025 earnings conference call. At this time, all participants are in listen-only ...

Arteris (NasdaqGM:AIP) Q4 2025 Earnings call February 12, 2026 04:30 PM ET Company ParticipantsCharlie Janac - CEOErica Mannion - Investor RelationsGus Richard - Managing DirectorNick Hawkins - CFOConference Call ParticipantsKevin Garrigan - Senior Equity Research AnalystMadison DePaula - AnalystOperatorGood afternoon, everyone, and welcome to the Arteris fourth quarter and full year 2025 earnings call. Please note this call is being recorded and simultaneously webcast. All material contained in the webcast ...

10X Genomics (NasdaqGS:TXG) Q4 2025 Earnings call February 12, 2026 04:30 PM ET Company ParticipantsAdam Taich - CFOCasey Woodring - VP of Equity ResearchCassie Corneau - Senior Director and Head of Investor Relations and Strategic FinanceDan Arias - Managing DirectorDoug Schenkel - Managing Director of Life Science Tools and DiagnosticsMichael Ryskin - Managing DirectorPatrick Donnelly - Managing DirectorSalem Salem - VP of Equity ResearchSerge Saxonov - Co-Founder and CEOSubbu Nambiar - Managing DirectorT ...

10X Genomics (NasdaqGS:TXG) Q4 2025 Earnings call February 12, 2026 04:30 PM ET Company ParticipantsAdam Taich - CFOCasey Woodring - VP of Equity ResearchCassie Corneau - Senior Director and Head of Investor Relations and Strategic FinanceDan Arias - Managing DirectorDoug Schenkel - Managing Director of Life Science Tools and DiagnosticsMichael Ryskin - Managing DirectorPatrick Donnelly - Managing DirectorSalem Salem - VP of Equity ResearchSerge Saxonov - Co-Founder and CEOSubbu Nambiar - Managing DirectorT ...

Bridgeline Digital (NasdaqCM:BLIN) Q1 2026 Earnings call February 12, 2026 04:30 PM ET Company ParticipantsAri Kahn - President and CEOThomas Windhausen - CFOConference Call ParticipantsCasey Ryan - Research AnalystOperatorGood day, everyone, and welcome to the Bridgeline Digital First Quarter 2026 earnings call. At this time, all participants are placed on a listen-only mode, and we will open the floor for your questions and comments after the presentation. It is now my pleasure to hand the floor over to y ...

Financial Data and Key Metrics Changes - As of December 31, 2025, the company had a cash balance of approximately $7 million [13] - Consolidated operating expenses for Q3 2026 were approximately $2.06 million, an increase of $250,000 or 13.6% compared to the same period last year [13] - The operating loss for the quarter increased to $2.06 million compared to $1.81 million in the prior year period [13] - For the nine-month period, operating expenses decreased significantly to $5.36 million, down $1.98 million or 27% from $7.34 million last year [14] Business Line Data and Key Metrics Changes - The company is advancing its Hemopurifier platform while maintaining disciplined cost control, with ongoing enrollment in the Australian oncology trial [5] - The second cohort of the oncology trial has seen two patients treated with Hemopurifier, with a third patient expected to be treated by the end of February [6][7] Market Data and Key Metrics Changes - There has been an uptick in the number of interested potential participants in the Australian oncology trial since contracting with TrialFax and Dedicated for recruitment [8] - The trial is designed to examine the number of Hemopurifier treatments needed to decrease extracellular vesicle concentrations and improve immune response against tumor cells [9] Company Strategy and Development Direction - The company is focused on advancing the Hemopurifier platform and exploring its compatibility with a simplified blood treatment system, which could enhance clinical and commercial flexibility [5][10] - Aethlon Medical is also exploring the potential of the Hemopurifier in treating conditions beyond oncology, including Long COVID and other diseases associated with extracellular vesicles [11][12] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the ongoing progress in the Australian oncology trial and the potential for the Hemopurifier to be integrated into oncology units and infusion centers, reducing invasiveness for patients [22][24] - The company is committed to cost containment while advancing its research and development efforts, particularly in the context of Long COVID [26] Other Important Information - The scientific rationale and full design of the Australian oncology trial have been published in a peer-reviewed journal, indicating the company's commitment to transparency and scientific rigor [10] - The next earnings call for the fiscal fourth quarter is scheduled to coincide with the filing of the annual report in June 2026 [16] Q&A Session Summary Question: Clarification on Cohort 2 treatment duration - Management confirmed that participants in Cohort 2 will receive two Hemopurifier treatments, maintaining the same follow-up period as Cohort 1 [19] Question: Impact of SLAMB system on treatment administration - The SLAMB system is expected to simplify the administration of Hemopurifier treatments, making it less invasive for patients and easier for hospital staff [22][24] Question: Cost-effective approach in R&D - Management emphasized the importance of cost containment while advancing research, focusing on in-house work and limiting external lab involvement [26] Question: Timeline for Data Safety Monitoring Board's decision - Management anticipates a decision from the Data Safety Monitoring Board on whether to advance to the third cohort on the same day or the next business day after the meeting [34] Question: Need for Cohort 3 - Management believes it is essential to conduct Cohort 3 to fully assess the efficacy of three treatments, based on historical data suggesting that more treatments may yield better results [60] Question: Regulatory hurdles for SLAMB system integration - The SLAMB system is not yet approved, and the company will need to conduct safety tests and treatments before integration with the Hemopurifier [45]

Dexcom (NasdaqGS:DXCM) Q4 2025 Earnings call February 12, 2026 04:30 PM ET Speaker14Ladies and gentlemen, good afternoon, and welcome to the Dexcom fourth quarter and fiscal year 2025 earnings release conference call. My name is Abby, and I will be your operator today. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session. During the question-and-answer session, if you have a question, please press star one on your touchtone phone. As a reminder, the ...

Alliance Entertainment (NasdaqCM:AENT) Q2 2026 Earnings call February 12, 2026 04:30 PM ET Speaker3Greetings, and welcome to Alliance Entertainment's second quarter fiscal year 2026 financial results conference call. At this time, all participants are in a listen-only mode. A question and answer session will follow the formal presentation. As a reminder, this conference is being recorded. I will now pass the call over to Paul Kuntz, a member of Alliance Entertainment's IR team at RedChip. Paul? Pardon me on ...